New antibody therapy targets tough AL amyloidosis cases
NCT ID NCT06769555
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This study was designed to test a drug called CM-336 in people with AL amyloidosis whose disease came back or didn't get better enough after initial treatment. The drug works by helping the immune system attack harmful cells. The trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.